Yescarta CAR-T Therapy Indications Expanded for B-Cell Lymphoma
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On December 23, 2022, Daiichi Sankyo Co., Ltd. and Kite, a Gilead company, announced that the CD19-targeted CAR-T cell therapy Yescarta (Axicabtagene ciloleucel) has received approval in Japan for expanded indications. As of December 20, 2022, Yescarta is authorized for use in adult patients with certain types of relapsed or refractory large B-cell lymphoma.
Clinical Evidence: ZUMA-7 Trial
The approval was supported by the results of the international Phase 3 ZUMA-7 trial. This study evaluated the efficacy and safety of Yescarta as a second-line treatment compared to the previous standard of care (high-dose chemotherapy followed by autologous stem cell transplant) in patients with relapsed or refractory large B-cell lymphoma.
Expanded Indications
The newly approved indications for Yescarta in Japan include:
- Diffuse large B-cell lymphoma (DLBCL)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Transformed follicular lymphoma (TFL)
- High-grade B-cell lymphoma (HGBL)
Impact on Patient Care
By providing a potent second-line option, Yescarta aims to improve outcomes for patients who have traditionally had limited choices after their initial treatment fails. Daiichi Sankyo and Kite expressed their commitment to making this innovative therapy available to a broader range of patients in need.
Source: Daiichi Sankyo Press Release - Yescarta Indication Expansion
#Lymphoma #DLBCL #Yescarta #CART #Immunotherapy #CancerResearch #JapanMedicine
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4